Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): Results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 615-622

  Kuchinskaya, Ekaterina ^a   Heyman, Mats ^b   Nordgren, Ann ^a   Söderhäll, Stefan ^b   Forestier, Erik ^c   Wehner, Peder ^d   Vettenranta, Kim ^e   Jonsson, Olafur ^f   Wesenberg, Finn ^g   Sahlén, Sigrid ^a   Nordenskjöld, Magnus ^a   Blennow, Elisabeth ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

9p21 deletion; Childhood acute lymphoblastic leukaemia; Interphase fluorescent in situ hybridization

Indexed keywords

BCR ABL PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 9P; CHROMOSOME 9P21; CHROMOSOME DELETION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOPHENOTYPING; INTERPHASE; MAJOR CLINICAL STUDY; MALE; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79951550913     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08532.x     Document Type: Article

References (34)

1. Batova, A., Diccianni, M.B., Nobori, T., Vu, T., Yu, J., Bridgeman, L. & Yu, A.L. (1996) Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood, 88, 3083-3090.
2. Bertin, R., Acquaviva, C., Mirebeau, D., Guidal-Giroux, C., Vilmer, E. & Cave, H. (2003) CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer, 37, 44-57.
3. Calero Moreno, T.M., Gustafsson, G., Garwicz, S., Grander, D., Jonmundsson, G.K., Frost, B.M., Makipernaa, A., Rasool, O., Savolainen, E.R., Schmiegelow, K., Soderhall, S., Vettenranta, K., Wesenberg, F., Einhorn, S. & Heyman, M. (2002) Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia, 16, 2037-2045.
4. Carter, T.L., Watt, P.M., Kumar, R., Burton, P.R., Reaman, G.H., Sather, H.N., Baker, D.L. & Kees, U.R. (2001) Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood, 97, 572-574.
5. Chim, C.S. & Kwong, Y.L. (2006) Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. Leukaemia & Lymphoma, 47, 815-825.
6. Chiosea, S., Krasinskas, A., Cagle, P.T., Mitchell, K.A., Zander, D.S. & Dacic, S. (2008) Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology, 21, 742-747.
7. Diccianni, M.B., Batova, A., Yu, J., Vu, T., Pullen, J., Amylon, M., Pollock, B.H. & Yu, A.L. (1997) Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leukemia Research, 21, 549-558.
8. Faderl, S., Kantarjian, H.M., Manshouri, T., Chan, C.Y., Pierce, S., Hays, K.J., Cortes, J., Thomas, D., Estrov, Z. & Albitar, M. (1999) The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clinical Cancer Research, 5, 1855-1861.
9. Florl, A.R. & Schulz, W.A. (2003) Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer, 37, 141-148.
10. Forestier, E., Gauffin, F., Andersen, M.K., Autio, K., Borgstrom, G., Golovleva, I., Gustafsson, B., Heim, S., Heinonen, K., Heyman, M., Hovland, R., Johannsson, J.H., Kerndrup, G., Rosenquist, R., Schoumans, J., Swolin, B., Johansson, B. & Nordgren, A. (2008) Clinical and cytogenetic features of pediatric dic(9;20) (p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer, 47, 149-158.
11. Graf Einsiedel, H., Taube, T., Hartmann, R., Eckert, C., Seifert, G., Wellmann, S., Henze, G. & Seeger, K. (2001) Prognostic value of p16(INK4a) gene deletions in pediatric acute lymphoblastic leukemia. Blood, 97, 4002-4004.
12. Haller, F., Lobke, C., Ruschhaupt, M., Cameron, S., Schulten, H.J., Schwager, S., von Heydebreck, A., Gunawan, B., Langer, C., Ramadori, G., Sultmann, H., Poustka, A., Korf, U. & Fuzesi, L. (2008) Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). The Journal of Pathology, 215, 253-262.
13. Hallor, K.H., Staaf, J., Jonsson, G., Heidenblad, M., Vult von Steyern, F., Bauer, H.C., Ijszenga, M., Hogendoorn, P.C., Mandahl, N., Szuhai, K. & Mertens, F. (2008) Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. British Journal of Cancer, 98, 434-442.
14. Heyman, M. & Einhorn, S. (1996) Inactivation of the p15INK4B and p16INK4 genes in hematologic malignancies. Leukaemia & Lymphoma, 23, 235-245.
15. Kawamata, N., Ogawa, S., Zimmermann, M., Kato, M., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., Flohr, T., Miller, C.W., Harbott, J., Ludwig, W.D., Stanulla, M., Schrappe, M., Bartram, C.R. & Koeffler, H.P. (2008) Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood, 111, 776-784.
16. Kees, U.R., Burton, P.R., Lu, C. & Baker, D.L. (1997) Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood, 89, 4161-4166.
17. Kustanovich, A.M., Savitskaja, T.V., Bydanov, O.I., Belevtsev, M.V. & Potapnev, M.P. (2005) Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia. Leukemia Research, 11, 1271-1265.
18. Maloney, K.W., McGavran, L., Odom, L.F. & Hunger, S.P. (1998) Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. Leukemia, 12, 1417-1421.
19. Mirebeau, D., Acquaviva, C., Suciu, S., Bertin, R., Dastugue, N., Robert, A., Boutard, P., Mechinaud, F., Plouvier, E., Otten, J., Vilmer, E. & Cave, H. (2006) The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica, 91, 881-885.
20. Moorman, A.V., Ensor, H.M., Richards, S.M., Chilton, L., Schwab, C., Kinsey, S.E., Vora, A., Mitchell, C.D. & Harrison, C.J. (2010) Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. The Lancet Oncology, 11, 429-438.
21. Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446, 758-764.
22. Mullighan, C.G., Heatley, S.L., Danner, S., Dean, M.M., Doherty, K., Hahn, U., Bradstock, K.F., Minchinton, R., Schwarer, A.P., Szer, J. & Bardy, P.G. (2008) Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood, 112, 2120-2128.
23. Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamada, N., Ohtake, S., Uike, N., Shimazaki, C., Toyama, K., Hirano, M., Mizoguchi, H., Kobyashi, Y., Furusawa, S., Saito, M., Emi, N., Yazaki, Y., Ueda, R. & Hirai, H. (1995) Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood, 86, 1548-1556.
24. Perez-Vera, P., Salas, C., Montero-Ruiz, O., Frias, S., Dehesa, G., Jarquin, B. & Rivera-Luna, R. (2008) Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution. Cancer Genetics and Cytogenetics, 184, 94-98.
25. Ramakers-van Woerden, N.L., Pieters, R., Slater, R.M., Loonen, A.H., Beverloo, H.B., van Drunen, E., Heyman, M., Moreno, T.C., Rots, M.G., van Wering, E.R., Kamps, W.A., Janka-Schaub, G.E. & Veerman, A.J. (2001) In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 112, 680-690.
26. Savola, S., Nardi, F., Scotlandi, K., Picci, P. & Knuutila, S. (2007) Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenetic and Genome Research, 119, 21-26.
27. Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Soderhall, S. & Taskinen, M. (2010) Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia, 24, 345-354.
28. Sulong, S., Moorman, A.V., Irving, J.A., Strefford, J.C., Konn, Z.J., Case, M.C., Minto, L., Barber, K.E., Parker, H., Wright, S.L., Stewart, A.R., Bailey, S., Bown, N.P., Hall, A.G. & Harrison, C.J. (2008) A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukaemia reveals genomic deletion, copy number neutral loss of heterozygosity and association with specific cytogenetic subgroups. Blood, 113, 100-107.
29. Takeuchi, S., Koike, M., Seriu, T., Bartram, C.R., Slater, J., Park, S., Miyoshi, I. & Koeffler, H.P. (1997) Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis. Leukemia, 11, 1636-1640.
30. Tsuzuki, S., Karnan, S., Horibe, K., Matsumoto, K., Kato, K., Inukai, T., Goi, K., Sugita, K., Nakazawa, S., Kasugai, Y., Ueda, R. & Seto, M. (2007) Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization. Cancer Science, 98, 698-706.
31. Walker, G.J., Flores, J.F., Glendening, J.M., Lin, A.H., Markl, I.D. & Fountain, J.W. (1998) Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer, 22, 157-163.
32. Woo, H.Y., Kim, D.W., Park, H., Seong, K.W., Koo, H.H. & Kim, S.H. (2005) Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia. Journal of Korean Medical Science, 20, 36-41.
33. Yamada, Y., Hatta, Y., Murata, K., Sugawara, K., Ikeda, S., Mine, M., Maeda, T., Hirakata, Y., Kamihira, S., Tsukasaki, K., Ogawa, S., Hirai, H., Koeffler, H.P. & Tomonaga, M. (1997) Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. Journal of Clinical Oncology, 15, 1778-1785.
34. van Zutven, L.J., van Drunen, E., de Bont, J.M., Wattel, M.M., Den Boer, M.L., Pieters, R., Hagemeijer, A., Slater, R.M. & Beverloo, H.B. (2005) CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia, 19, 1281-1284.